Alterity Therapeutics Files June 2026 Corporate Presentation

Alterity Therapeutics Limited filed a Form 6-K with the SEC on June 16, 2026, to provide its Corporate Presentation for June 2026. The filing serves as a routine regulatory update to incorporate the presentation by reference into several of the company\'s existing Registration Statements on Form S-8 and Form F-3. As a development-stage enterprise, Alterity Therapeutics uses such presentations to provide updates on its corporate strategy and clinical pipeline progress to investors and stakeholders. The filing itself does not disclose new clinical trial results, regulatory approvals, or specific financial data, but rather acts as a vehicle for the disseminated presentation materials. The document was signed by Julian Babarczy, Chairman of the Board. No specific upcoming trial result dates were mentioned in the primary text of the 6-K filing.